Acute lymphoblastic leukaemia develops in both children and adults, with a peak incidence
between 1 year and 4 years. Most acute lymphoblastic leukaemia arises in healthy …

Abstract The EU-supported EuroFlow Consortium aimed at innovation and standardization
of immunophenotyping for diagnosis and classification of hematological malignancies by …

Chimeric antigen receptor (CAR) T cells have demonstrated clinical benefit in patients with
relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). We undertook a …

Importance Minimal residual disease (MRD) refers to the presence of disease in cases
deemed to be in complete remission by conventional pathologic analysis. Assessing the …

Assessment of minimal residual disease (MRD) has acquired a prominent position in
European treatment protocols for patients with acute lymphoblastic leukemia (ALL), on the …

In patients with acute lymphoblastic leukemia (ALL), treatment response is increasingly
evaluated with minimal residual disease (MRD) assays. ALL cells can be recognized by …

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. While there are
a number of well‐recognized prognostic biomarkers at diagnosis, the most powerful …

Simple Summary Standardization of flow-cytometric assessment of minimal residual disease
in acute lymphoid leukemia (ALL) is necessary to allow concordant multicentric application …

MRD is replacing morphology to measure treatment response in ALL and is being used, with
promising results, for risk-stratification in clinical protocols. Recent studies provide further …

Background Flow‐cytometric minimal residual disease (FC‐MRD) monitoring is a well‐
established risk‐stratification factor in B‐lymphoblastic leukemia/lymphoma (‐B‐ALL) and is …